Full-Time

Senior Manager Manufacturing Systems

Drug Substance Automation

Posted on 7/4/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$173.6k - $199.1k/yr

+ Bonus + Stock-based long-term incentives

Thousand Oaks, CA, USA

In Person

Category
Mechanical Engineering (1)
Requirements
  • High school diploma / GED and 12 years of Engineering experience OR
  • Associate’s degree and 10 years of Engineering experience OR
  • Bachelor’s degree and 8 years of Engineering experience OR
  • Master’s degree and 6 years of Engineering experience OR
  • Doctorate degree and 2 years of Engineering experience
  • Minimum of 2 years experience directly managing people and/or leadership experience leading teams, projects, programs, or directing the allocation of resources.
Responsibilities
  • Lead a team of automation professionals and serve as the main point of contact for automation function for Drug Substance Supply manufacturing.
  • Define, drive, and deliver the automation and process control strategies within Drug substance manufacturing.
  • Serve as an experienced advisor to senior level management and ensure the automation solutions & strategy development aligns with Manufacturing Process requirements.
  • Strategic and tactical management and leadership in providing 24x7 day-to-day operational support and capital project support.
  • Develop the scope and life cycle upgrade plan in partnership with OEM, Manufacturing & Amgen Operations Digital Transformation and Innovation (DTI) teams.
  • Work with diverse groups (Manufacturing, Quality, Process Development, DTI, Safety, Global Engineering) and drive new business processes to ensure continuous and sustained automation improvement initiatives.
  • Ensure plant readiness and quality and regulatory compliance for internal audits, external agency audits, and partner audits for the automation systems.
  • Ensure the safety of all personnel during plant operations, maintenance, and project implementation activities.
  • Develop expense budget forecasts and adhere to the budgeted expenses.
  • Responsible for Staff Management for on-site work and rotational automation on-call support planning and execution.
  • Prepare and communicate plant automation highlights and lowlights on a weekly basis to the key collaborators.
  • Ensure Amgen Enterprise cyber resiliency compliance is maintained at 100%.
  • Responsible for ensuring that the operational functionalities for each process unit operation, cleaning & sterilization systems are configured accurately in the automation systems in line with Process Transfer Documents.
  • Develop, maintain and implement preventive maintenance activities with the team for all automation assets supporting Drug Substance Supply operations.
  • Responsible for periodically assessing and ensuring sufficient spare parts for the Drug Substance Manufacturing & utilities automation systems are maintained within the Central Inventory.
  • Ensure the right processes/systems are in place to capture 100% quality compliance for the right-first-time (RFT) delivery of automation solutions.
  • Ensure that Electronic Reporting functionality is incorporated for all Drug Substance unit operations for production Batch records, cleaning, and sterilization systems, including Audit trail and version control.
  • Responsible for ensuring service contracts with all OEMs & Integrated Service Providers are established for automation engineering service and support needs.
  • Responsible for designing, developing, deploying, maintaining, and performing backup & restoration of manufacturing process control systems, automation, and field instrumentation technologies.
  • Responsible for Automation design, experience in process control engineering, and trouble shooting with GMP biopharmaceutical production facility equipment/systems such as media, harvest, bioreactors, chromatography, vial filtration, and ultrafiltration/diafiltration, and integrating various OEM automation software.
  • Responsible for leading continuous improvements resulting in enhanced safety, system reliability, and productivity (e.g., Cycle times, reduced plant utilities usage, etc.) related to Drug Substance Plant Operations.
  • Lead/support technical root cause analysis, incident investigations, and trouble shooting process control issues related to plant operations.
  • Responsible for ensuring that all the direct reports are adequately trained and follow all GMP standards and procedures by managing the team's internal and external training needs.
  • Responsible for ensuring the automation team actively participates in daily/weekly multi-functional work center team meetings.
  • Responsible for assessing manufacturing needs and developing plans for automation system expansion to support increased plant run rate.
  • Mentor the staff for their career development.
Desired Qualifications
  • Degree in Chemical Engineering or Electrical Engineering.
  • 10+ years of relevant work experience in Life Science Manufacturing with a major focus on process control and automation systems.
  • Emerson DeltaV Batch Distributed Control System (ISA Standard S88)
  • Rockwell Automation SCADA and PLC Platform.
  • Electronic Batch Reporting Systems Design and implementation
  • Process Control Network design including network segregation (ISA Standard S95)
  • Process Control Systems: Virtual Infrastructure design and implementation and ability to perform advanced troubleshooting activities
  • System Integration using Ethernet IP, OPC, Foundation Fieldbus, Profibus, and DeviceNet technologies.
  • Compliance and regulatory requirements such as 21 CFR Part 11
  • The ideal individual must be a self-directed team player ready to mentor and develop engineering staff and embrace a team-based culture that relies on collaboration for effective decision-making.
  • Experienced in leading plant support team focused on troubleshooting, on-time support, plant maintenance, system lifecycle management, Spare Parts management, and Service level agreements.
  • Experienced in New Product Introduction to engineer automation systems to meet the process requirements.
  • Experienced in talent management (recruit, train, retain and performance management)
  • Experienced in managing internal and external communication with key stakeholders.
  • Experienced in execution excellence to ensure Right the First Time (RFT) delivery of automation engineering services to the plant operations.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE